Reportlinker Adds Opportunities in Emerging Pharma Markets: Strategies for Optimizing Growth in key Regions and Therapeutic Areas

Wednesday, April 7, 2010 Research News
Email Print This Page Comment bookmark
Font : A-A+

NEW YORK, April 6 announces that a new market research report is available in its catalogue:

Opportunities in Emerging Pharma Markets: Strategies for optimizing growth in key regions and therapeutic areas

The flurry of recent industry acquisitions and alliances focused on product portfolios and distribution networks in the Emerging Markets underscores the attractiveness of these areas for the Pharmaceutical industry. This report outlines many of these recent industry alliances, by companies including Pfizer, GSK, Novartis, Abbott, Daiichi Sankyo and others. Many of these alliances have been focused on obtaining the Pharmaceuticals, Generics, Vaccines, OTC's, Hepatitis and HIV/AIDS agents and Biosimilars appropriate for the Emerging markets. Other companies still seeking alliances are identified, as well as those that appear to be potential generic and Biosimilar supply partners.

This report provides market forecasts for the major Emerging markets, by IMS and by key industry players. It also outlines the opportunities and challenges presented by market, the major companies focusing on growth in these markets, and the sales and marketing strategies being implemented by specific industry leaders.

Key features of this report

Scope of this report

Key Market Issues

Key findings from this report

- The vast opportunities for Pharmaceuticals in China appear more attainable than ever given the government's funding of major Healthcare Reforms to increase healthcare access, infrastructure and services between 2009 and 2011. These healthcare reforms aimed at expanding medical insurance and access while decreasing costs are expected to increase pharmaceutical volume at reduced prices.

- India, with its population of 1.1 billion, high levels of poverty and unmet medical needs and low healthcare expenditures continues to present challenges for the global industry. Opportunities include manufacturing skills including Biosimilar manufacturing. However, the lack of Intellectual Property recognition for several biologics, that prompted Novartis's shift of R+D investment from India to China, is a concern for the innovative industry.

- The large market shares of generics in the Emerging markets have resulted in numerous generic supply deals by companies including Pfizer, GSK, Sanofi Aventis, Novartis, Daiichi Sankyo and Abbott. Other companies that are seeking generic portfolios through alliances or acquisitions include Astra Zeneca, Lilly, J&J and Merck.

- Mylan and Teva appear to be potential alliance partners for companies seeking generics, based on their product portfolios and limited Emerging Market presence.

Key questions answered

- What are the pharmaceutical market sizes, growth forecasts and unmet medical needs in the Emerging markets?

- Is there one definitive list of Emerging markets for Pharmaceuticals?

- What are the opportunities and challenges presented by the major Emerging Market countries and regions?

- How can companies evaluate which Emerging markets offer the greatest opportunities for their growth?

- What are the expectations for the industry impact of the Chinese government's comprehensive plan for Healthcare reform and expansion?

- Which companies are current industry leaders in terms of Emerging market sales?

Companies mentioned

Abbott , Astra Zeneca , Bayer , BMS , Boehringer Ingelheim , Daiichi Sankyo , Eisai , GSK , J&J , Lilly , Merck , Mylan , Novartis , Novo Nordisk , Pfizer , Roche , Sanofi Aventis , Takeda , Teva ,

Table of Contents

Opportunities In Emerging Pharma Markets

Executive summary 10

Overview of emerging markets for pharmaceuticals 10

Emerging market profiles by countries and regions 11

Emerging market growth strategies by leading companies 12

Emerging market opportunities by product segment 13

Recommendations for success in emerging markets 14

Chapter 1 Overview of emerging markets

for pharmaceuticals 16

Summary 16

Introduction 17

Pharmerging countries 18

2007 forecast 18

2008 forecast 19

Multiple classifications of emerging markets 23

China is the largest growth opportunity 25

Emerging market opportunities 26

Emerging market challenges 27

Chapter 2 Emerging market profiles by

country and regions 30

Summary 30

Brazil 32

Market size and forecast 32

Demographics 33

Opportunities and challenges 33

Recent acquisitions and alliances 34


China 34

Market size and forecast 34

Demographics 35

Overview 35

Market segments 36

Opportunity: China's healthcare expansion plan 37

Impact of Chinese healthcare reforms 38

Additional opportunities and challenges 39

China market segmentation: Tier 1, 2 and 3 cities 39

Leading industry company strategies in China 41

Recent acquisitions and alliances 42

India 42

Market size and forecast 42

Demographics 42

Overview 42

Opportunities and challenges 43

Leading industry company strategies 44

Recent acquisitions and alliances 44

South Korea 44

Market size and forecast 44

Demographics 44

Leading industry company strategies 45

Mexico 45

Market size and forecast 45

Demographics 45

Leading industry company strategies 46

Recent acquisitions and alliances 46

Russia 46

Market size and forecast 46

Demographics 47

HIV prevalence 47

Market overview 48

Opportunities and challenges 48

Leading industry company strategies 49

Recent acquisitions and alliances 50

Turkey 50

Market size and forecast 50

Demographics 50

Market overview 50

Opportunities and challenges 50

Leading industry company strategies 51

Recent acquisitions and alliances 51

Other emerging Asia-Pacific markets 52

Demographics 52

Opportunities and challenges 52

Leading industry company strategies 54

Other emerging Latin America markets 56

Demographics 56

Leading industry company strategies 56


Recent acquisitions and alliances 57

Other emerging Central and Eastern European markets 57

Demographics 57

Leading industry company strategies 58

Recent acquisitions and alliances 58

Other emerging Middle East and Africa markets 59

Chapter 3 Emerging market growth

strategies by leading companies 62

Summary 62

Abbott 63

AstraZeneca 64

Bristol Myers Squibb 65

Bayer 65

Boehringer Ingelheim 66

Daiichi Sankyo 67

Eisai 68

GSK 68

Generics 70

Vaccines 71

HIV Agents 71

Asia-Pacific 71

China 71

India 72

Developing world initiatives 72

J&J 73

Lilly 73

Merck 74

China 75

Developing world initiatives 75

Mylan 76

Novartis 77

Generics 77

China 78

Novo Nordisk 78

Pfizer 79

Generics 80

China 81

Innovative strategies 81

Roche 82


Sanofi-Aventis 83

Takeda 84

Teva 84

Chapter 4 Emerging market opportunities

by product segment 88

Summary 88

Patented and innovative products 89

Generics/branded generics 90

Biosimilars 91

OTCs 93

HIV and hepatitis agents 94

HIV agents 94

Hepatitis agents 96

Vaccines 97

Industry vaccine leaders 98

Opportunities 99

Challenges 99

Recent vaccine acquisitions and alliances 100

Developing world vaccines and medicines 101

Developing market disease numbers 101

Chapter 5 Recommendations for success in

emerging markets 106

Summary 106

Product offering 107

Country selection 108

Partnerships 109

Strategy development 109

Competitor awareness 109

Tailor marketing to the market 110

Market "glocally" 111

Effective promotion 112

Region specific planning 113

Security risks 114


Security of data and manufacturing supply chain 114

Protection of company image and reputation 115

Protection of assets 115

Index 116

Appendix 119

References 119

List of Figures

Figure 1.1: 2013 forecast of seven emerging markets ($bn), 2008-2013 20

Figure 5.2: Product opportunities 108

List of Tables

Table 1.1: 2013 forecast of seven emerging markets, 2009 20

Table 1.2: 2008 sales in the seven major emerging markets, 2009 22

Table 1.3: Prevalence of diabetes (m), 2000-2030 25

Table 2.4: Statistics: Seven major seven emerging pharmaceutical markets 32

Table 2.5: Tier 1, 2 and 3 Chinese cities, 2008 40

Table 2.6: Other emerging Asia-Pacific Markets: Statistics 52

Table 2.7: Diabetics (millions) 53

Table 2.8: Other emerging Latin America Markets: Statistics 56

Table 2.9: Other emerging Central and Eastern European markets: statistics 57

Table 4.10: Marketed and pipeline biosimilars by company 92

Table 4.11: Annual deaths due to HIV/AIDS by country 95

Table 4.12: HIV prevalence (millions), 2007 96

Table 4.13: Select companies with vaccines by type 98

To order this report:

Pharmaceutical Industry: Opportunities in Emerging Pharma Markets: Strategies for optimizing growth in key regions and therapeutic areas

More Market Research Report

Check our Company Profile, SWOT and Revenue Analysis!

Contact Nicolas Bombourg



US: (805)652-2626

Intl: +1 805-652-2626

-- Coverage of numerous information sources for a comprehensive and up-to-date overview of the subject. -- Evaluation of the opportunities and challenges presented by the 7 major emerging markets as well as Other Asia-Pacific, Latin America, Central and Eastern Europe and Middle East and Africa markets. -- Coverage of market profiles by country and region, including market and epidemiological data -- Coverage of emerging market growth goals, strategies and alliance activity by leading companies -- Extensive analysis of recent government plans for healthcare reform and expanded access in China

SOURCE Reportlinker

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z


News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store